Yelak Biru/LinkedIn
Jul 4, 2025, 04:52
Yelak Biru: We are getting used to monthly approval of “something” for myeloma
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, shared a post by Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, adding:
“We are getting used to monthly approval of “something” for myeloma. I welcome that! Patient-centricity of the drug, the company, and, of course, efficacy, will be a differentiator as we have more of these drugs approved.”
Quoting Rahul Banerjee‘s post:
“Excellent – linvo approved for 🇺🇸 pts with myeloma!
Q2W and Q4W built into approval
FDA forced 4 prior lines again
From press release: ‘0.95 month median time to first response.’ When I was a kid, time to 1st response with #MMsm BCMA bsAbs was always exactly 1.2 mo.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 9, 2025, 14:14